

Frontiers in Clinical Drug Research

(Anti Infectives)



Editor:
Atta-ur-Rahman, *FRS*

Bentham Books

Frontiers in Clinical Drug Research-Anti Infection

(Volume 8)

Edited by

Atta-ur-Rahman, FRS

*Honorary Life Fellow,
Kings College,
University of Cambridge,
Cambridge,
UK*

Frontiers in Clinical Drug Research-Anti Infectives

Volume # 8

Editor: Prof. Atta-ur-Rahman, *FRS*

ISSN (Online): 2352-3212

ISSN (Print): 2452-3208

ISBN (Online): 978-981-5039-41-2

ISBN (Print): 978-981-5039-42-9

ISBN (Paperback): 978-981-5039-43-6

©2021, Bentham Books imprint.

Published by Bentham Science Publishers Pte. Ltd. Singapore. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“**Work**”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.net.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.
3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the

need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.

3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Pte. Ltd.

80 Robinson Road #02-00

Singapore 068898

Singapore

Email: subscriptions@benthamscience.net



CONTENTS

PREFACE	i
LIST OF CONTRIBUTORS	ii
CHAPTER 1 MONOCLONAL ANTIBODIES AS THERAPEUTIC AGENTS FOR INFLAMMATORY DISEASES	1
<i>Jéssica Bairos, Emanue V. Capela Ana P.M. Tavares and Mara G. Freire</i>	
INTRODUCTION	1
MONOCLONAL ANTIBODIES	3
Structure and Properties of Antibodies	3
Relevance and Applications of Monoclonal Antibodies	7
Monoclonal Antibodies Therapeutics Market	9
INFLAMMATION OVERVIEW	10
G-Protein-Coupled Receptors	11
Adhesion Receptors	12
Pattern Recognition Receptors	13
Fc-Receptors	15
Cytokine Receptors	16
MONOCLONAL ANTIBODY-BASED THERAPIES FOR THE TREATMENT OF INFLAMMATION	21
Interleukin-8 and Interleukin-6	21
Anti-Interleukin-8 and Anti-Interleukin-6 mAbs	23
Role of Anti- IL-6 mAbs in the Severe Acute Respiratory Syndrome-2	26
Other Recently Approved Monoclonal Antibodies for Inflammatory Diseases	29
Risankizumab-rzaa	32
Polatuzumab Vedotin-piiq	33
Brolucizumab-dbli	34
Teprotumumab-trbw	36
Satralizumab-mwge	37
CONCLUDING REMARKS	38
CONSENT FOR PUBLICATION	40
CONFLICT OF INTEREST	40
ACKNOWLEDGEMENTS	40
REFERENCES	40
CHAPTER 2 PHARMACOTHERAPY OF EMERGING ANTIVIRAL AGENTS	55
<i>Gaurav M Doshi, Hemen S Ved, Ami P Thakkar, Nirav Y. Bhatia and Prachi M</i>	
Pimple1	55
INTRODUCTION	56
EXISTING ANTIVIRAL CLASSIFICATION	57
5-substituted 2'-deoxyuridine Analogs	57
Nucleoside Analogs	57
Pyrophosphate Analogs	58
Nucleoside Reverse Transcriptase Inhibitors	58
Nonnucleoside Reverse Transcriptase Inhibitors	59
Entry Inhibitors	59
Acyclic Guanosine Analogs	60
Acyclic Nucleoside Phosphonate Analogs	60
HCV NS5A/NS5B Inhibitors	61
HIV and HCV NS3/4A Protease Inhibitors	61
Integrase Inhibitors	62

NEWER ANTIVIRAL AGENTS	62
For HSV Infections	62
<i>Brincidofovir</i>	62
<i>UB-621</i>	65
<i>Amenamevir (ASP2151)</i>	66
<i>Pritelivir</i>	67
For HPV Infections	68
<i>GX-17, NT-17</i>	68
<i>Teslexivir, AP611074, BTA074</i>	69
<i>ABI 1968; HTI-1968</i>	71
For VZV infections	72
<i>FV-100, Valnivadine</i>	72
For RSV Infections	75
<i>MEDI8897/ Nirsevimab:</i>	75
<i>PC786</i>	76
<i>JNJ-53718678, NJ-678; JNJ-8678, Rilematovir</i>	77
For HIV infections	78
<i>Budigalimab</i>	78
<i>GSK3640254</i>	79
<i>UB-421</i>	80
For HCV infections	82
<i>Uprifosbuvir</i>	82
For HBV Infections	83
<i>Selgantolimod</i>	83
<i>JNJ-73763989</i>	85
<i>VIR-2218</i>	86
CONCLUSION	87
ABBREVIATIONS	88
CONSENT FOR PUBLICATION	89
CONFLICT OF INTEREST	89
ACKNOWLEDGEMENTS	89
REFERENCES	89
CHAPTER 3 ANTIVIRAL ACTIVITY OF VITAMIN D AND COVID 19: CURRENT UNDERSTANDING	101
<i>Mahmood A. Al-Azzawi and Moustafa A. Sakr</i>	
INTRODUCTION	102
VITAMIN D AND MICROBIAL INFECTION: INSIGHT ON MECHANISMS BASED-INHIBITION	105
THE ROLE OF VITAMIN D IN COVID-19 DISEASE	111
CLINICAL AND EPIDEMIOLOGICAL FINDINGS CONCERNING COVID-19	116
THE ROLE OF VITAMIN D IN COVID-19 INFECTIONS AND OUTCOMES: AN INSIGHT ON CURRENT STUDIES	119
RECOMMENDATIONS	146
CONCLUSION AND PERSPECTIVES	150
CONSENT FOR PUBLICATION	152
CONFLICT OF INTEREST	152
ACKNOWLEDGEMENTS	152
REFERENCES	152
CHAPTER 4 ANTI-INFECTIVES TO COMBAT LEISHMANIASIS	174
<i>Shalini Roy, Anindita Ukil and Pijush K. Das</i>	

INTRODUCTION	175
Leishmaniasis	175
Causative Parasite and the Vector	175
Life Cycle	176
Mode of Transmission	176
Disease Manifestations	177
Current Treatment Options	177
Evation of Host Defense	178
Host Resistance Factor	178
DRUGS FOR TREATMENT OF LEISHMANIASIS	178
Antimonials	178
<i>Species-specific Diversity</i>	178
<i>Clinical Resistance</i>	179
<i>Advantages and Disadvantages</i>	180
Amphotericin B	181
<i>Species-specific Diversity</i>	181
<i>Clinical Resistance</i>	181
<i>Advantages and Disadvantages</i>	182
AmBisome	182
Miltefosine as Third-line Treatment	183
<i>Clinical Resistance</i>	184
<i>Advantages and Disadvantages</i>	184
Paromomycin (Aminosidine)	185
<i>Species-specific diversity</i>	185
<i>Clinical Resistance</i>	185
INVESTIGATIONAL DRUGS	186
Azoles	186
<i>Species Variation</i>	186
<i>Clinical Resistance</i>	186
Nitroimidazole Compound	187
<i>Fexinidazole</i>	187
<i>PA-824</i>	187
Sitamaquine	187
Nucleoside Analogues	188
Quinoline Derivatives	188
Aminoquinaldine Compounds	189
Naphthoquinones	189
Doxorubicin	189
OTHER INVESTIGATIONAL AGENTS	190
Nano-amphotericin B	190
Carbon Nanotubes	190
Oral Lipid-based Formulation of Amphotericin B	191
Other Amphotericin B Preparations	191
PRESENT SCENARIO PERTAINING TO THE USE OF THERAPEUTICS	191
FUTURE AGENDA FOR BETTER REMEDIAL MEASURES	192
New Targets, New Drugs	192
Cost and Distribution of Drugs	195
Emerging Roles of Immunomodulators	195
Scopes for Combinatorial Therapies	196
Vaccines: a Potential Therapeutic Angle	197
Scopes for Advancement of Techniques to Explore New Leads and Diagnostics	198

CONCLUSION	199
CONSENT FOR PUBLICATION	199
CONFLICT OF INTEREST	199
ACKNOWLEDGEMENTS	199
REFERENCES	199

CHAPTER 5 ANTHELMINTIC DRUG DISCOVERY: CURRENT SITUATION AND FUTURE PERSPECTIVES 209

María Gabriela Blanco María José De Rosa and Diego Rayes

INTRODUCTION TO PARASITIC NEMATODES	210
Helminths: Phylum Nematoda	210
Overview of Nematode Infections	211
Intestinal Infections	213
Tissue Infections	214
PARASITIC NEMATODES	215
Intestinal Nematodes	215
<i>Ascariasis</i>	215
Trichuriasis	216
Hookworm Infections	217
Strongyloidiasis	218
Enterobiasis	220
Tissue Nematodes	221
<i>Filariasis</i>	221
<i>Lymphatic Filariasis (LF)</i>	222
<i>Subcutaneous Filariasis</i>	223
<i>Onchocerciasis</i>	223
<i>Loiasis</i>	224
<i>Trichinellosis</i>	225
ANTHELMINTIC DRUGS	227
Benzimidazoles	227
Imidazothiazoles and Tetrahydropyrimidines	228
Macrocyclic Lactones	229
Piperazine Derivatives	230
Promising Drugs	232
<i>Tribendimidine</i>	232
<i>Cyclooctadepsides</i>	232
<i>Pyrimidine Derivative</i>	233
NEMATODE INFECTION TREATMENT	233
Intestinal Infections	233
<i>Ascariasis</i>	233
Trichuriasis	234
Hookworm Infections	234
Strongyloidiasis	234
Enterobiasis	234
Tissue Infections	235
<i>Lymphatic Filariasis (LF)</i>	235
Subcutaneous Filariasis	235
<i>Onchocerciasis</i>	235
<i>Loiasis</i>	236
<i>Trichinellosis</i>	236
WHO and Mass Drug Administration	237

THE NEED TO DEVELOP NEW ANTHELMINTIC CONTROL STRATEGIES	238
C. ELEGANS: A NEMATODE MODEL FOR DRUG DISCOVERY	240
CONCLUDING REMARKS	243
ACKNOWLEDGEMENTS	243
CONSENT FOR PUBLICATION	243
CONFLICT OF INTEREST	244
AUTHOR CONTRIBUTIONS	244
LIST OF ABBREVIATIONS	244
REFERENCES	244
CHAPTER 6 THERAPEUTIC TARGETS FOR EMERGING ZIKA VIRUS INFECTION AND VACCINES IN CLINICAL TRIALS	260
<i>Deepthi Ramesh, Balaji Gowrivel Vijayakumar and Tharanikkarasu Kannan</i>	
ZIKA VIRUS DISCOVERY AND EPIDEMIOLOGY	260
ZIKA VIRUS GENOME STRUCTURE AND LIFE CYCLE	263
Virion Structure	263
Viral Entry and Replication Cycle in the Host	265
MOLECULAR PATHOGENESIS	267
Zika Virus Transmission	267
Clinical Manifestations	269
Diagnostics	270
Prevention and Control of ZIKV Transmission	271
VIRAL THERAPEUTICS	274
Zika Virus Structural Proteins as Drug Targets	274
Zika Virus Nonstructural Proteins as Drug Targets	275
Host Cell Proteins as Drug Targets	276
Drug Discovery Initiatives for Treating Zika Virus Infection	277
Nucleoside and Nucleotide Analogs	277
Non-nucleoside RNA Polymerase Inhibitor	278
Protease Inhibitors	279
Fusion Inhibitors	281
Inhibitors of Host Nucleoside Biosynthesis	282
Zika Virus Vaccine	283
SUMMARY AND CONCLUDING REMARKS	287
CONSENT FOR PUBLICATION	287
CONFLICT OF INTEREST	287
ACKNOWLEDGEMENT	288
REFERENCES	288
CHAPTER 7 AGRO-INDUSTRIAL WASTE: NEW SOURCE OF RAW MATERIAL FOR THE CONTROL OF AMERICAN FOULBROOD IN HONEY BEES	300
<i>Pablo Giménez-Martínez^{1,2}, Cristina Ramírez³, Azucena Iglesias^{1,2}, Florencia Fangio⁴, Sandra Churio, Matias Maggi and Sandra Fuselli</i>	
INTRODUCTION	301
American Foulbrood	301
<i>Characteristics of the Disease</i>	301
<i>Paenibacillus Larvae, the Causal Agent</i>	301
<i>Pathogenesis and Symptoms</i>	302
<i>Disease Control</i>	302
<i>Conventional Chemotherapy Treatment</i>	302
<i>Alternative Chemotherapy Treatment</i>	303
<i>Bioactive Compounds as an Alternative to Synthetic Antibiotics</i>	304

<i>Obtaining Plant Extracts Rich in SM</i>	304
<i>Source of Raw Materials for Obtaining Bioactive Compounds</i>	305
<i>Humulus Lupulus L.</i>	305
SECTION 1 - CHEMICAL ANALYSIS	307
MATERIAL AND METHODS	307
<i>Vegetal Material</i>	307
SolidLiquid Extraction of Bioactive Compounds	308
Secondary Metabolites Characterization	308
Statistics	309
RESULTS	309
Yield of Extraction of H. Lupulus L.	309
<i>Chemical Composition Analysis</i>	310
<i>Classification of Hop Varieties</i>	311
DISCUSSION	313
Extraction Performance of H. Lupulus L.	313
Effect of Fertilizer Application on the Chemical Composition of H. Lupulus L.	313
Chemical Analysis	314
Chemical Classification of Hop Varieties	315
SECCION 2 – BIOACTIVITY	316
MATERIAL AND METHODS	316
Workplace	316
Paenibacillus Larvae: Strains and Culture Conditions	316
Honeybees	317
Plant Extracts, Preparation and Determination of Antimicrobial Activity	317
Apis Mellifera Toxicity Assay	318
Molecular Analysis: Effects on Bee Larvae AMP Genes	319
RNA Extraction	319
RNA Quantification	320
DNase Treatment	320
Reverse Transcript	320
Real-Time PCR for the Detection of the β Actin, Abaecin, Defensin-2 and Hymenoptaecin Genes	320
Quantitative Real-Time PCR (qPCR)	321
Statistic	321
RESULTS	321
Antimicrobial Activity of Hop Leaves (Humulus Lupulus L.)	321
<i>Apis Mellifera Toxicity</i>	324
Molecular Analysis	328
DISCUSSION	329
Antimicrobial Activity	329
Apis Mellifera Toxicity	332
Adult HoneyBees	332
Apis Mellifera Larvae	332
Molecular Analysis	333
CONCLUSION	334
Effect of Fertilizer Application on the Chemical Composition of Secondary Metabolites in Hop Crops:	334
Analysis of Antimicrobial Activity against Paenibacillus Larvae:	334
Analysis of the Toxicity of Plant Extracts and Organic Compounds Analyzed in Bees (A. Mellifera)	335

Molecular Analysis of the Effect of the Hydroalcoholic Extract of the Victoria Variety on the Expression of Genes of the Autoimmune System in Bee larvae	335
CONSENT FOR PUBLICATION	335
CONFLICT OF INTEREST	335
ACKNOWLEDGEMENTS	335
REFERENCES	336
SUBJECT INDEX	566

PREFACE

The 8th volume of **Frontiers in Clinical Drug Research – Anti Infectives** comprises seven chapters that cover several important topics including the role of monoclonal antibodies, emerging antiviral agents, and the current situation on antiparasitic drug discovery.

In chapter 1, Capela *et al.* discuss the role of monoclonal antibodies as therapeutic agents for inflammatory diseases. Doshi *et al.* explore the pharmacotherapy of emerging antiviral agents in chapter 2 of the volume. Al-Azzawi and Sakr discuss how vitamin D can be used as a preventive or treatment agent for COVID-19. Das *et al.*, in chapter 4, present an overview of anti-infectives to combat leishmaniasis. Rayes *et al.*, in chapter 5, summarize the current situation on antiparasitic drug discovery and discuss the use of *C. elegans* at the initial steps of drug development. In the next chapter, Kannan *et al.* discuss the emergence of the Zika virus and its detailed genome structure and replication cycle. Fuselli *et al.*, in the last chapter of the volume, give an insight on agro-industrial waste, a new source of raw material for the control of American foulbrood in honey bees.

I would like to thank all the authors for their excellent contributions that should be of great interest. I would also like to thank the editorial staff of Bentham Science Publishers, particularly Mr. Mahmood Alam (Editorial Director of Bentham Science Publishers), Mr. Obaid Sadiq (In-charge Books Department), and Miss Asma Ahmed (Senior Manager Publications) for their support.

Atta-ur-Rahman, FRS
Kings College
University of Cambridge
Cambridge
UK

List of Contributors

- Ami P Thakkar** Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India
- Azucena Iglesias** Instituto de Investigaciones en Producción, Sanidad y Ambiente (IIPROSAM), CONICET, UNMdP, Centro de Asociación Simple CIC PBA, Mar del Plata, Argentina
Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
- Ana P.M. Tavares** CICECO – Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
- Anindita Ukil** Department of Biochemistry, University of Calcutta, Kolkata 700019, India
- Balaji Gowrivel Vijayakumar** Department of Chemistry, Pondicherry University, Kalapet, Puducherry, 605014, India
- Cristina Ramírez** Depto. de Química y Bioquímica, FCEyN, Universidad Nacional de Mar del Plata, Argentina
- Deepthi Ramesh** Department of Chemistry, Pondicherry University, Kalapet, Puducherry, 605014, India
- Diego Rayes** Laboratorio de Neurobiología de Invertebrados, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB) CCT UNS-CONICET. Bahía Blanca, Argentina, Camino La Carrindanga Km 7, Bahía Blanca, Argentina
Dpto de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur. Bahía Blanca, Argentina, San Juan 670, Bahía Blanca, Argentina
- Emanuel V. Capela** CICECO – Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
- Florencia Fangio** Departamento de Química, Facultad de Ciencias Exactas y Naturales, Instituto de Investigaciones Físicas de Mar del Plata (IFIMAR), CONICET, Universidad Nacional de Mar del Plata, Mar del Plata, Buenos Aires, Argentina
- Gaurav M Doshi** Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India
- Hemen S Ved** Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India
- Jéssica Bairos** CICECO – Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
- Mara G. Freire** CICECO – Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal
- Mahmood A. Al-Azzawi** Department of Pathological Analysis Techniques, College of Medical & Health Technologies Ahl Al Bayt University, Karbala, Iraq

María Gabriela Blanco	Laboratorio de Neurobiología de Invertebrados, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB) CCT UNS-CONICET. Bahía Blanca, Argentina, Camino La Carrindanga Km 7, Bahía Blanca, Argentina Dpto de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur. Bahía Blanca, Argentina, San Juan 670, Bahía Blanca, Argentina
María José De Rosa	Laboratorio de Neurobiología de Invertebrados, Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB) CCT UNS-CONICET. Bahía Blanca, Argentina, Camino La Carrindanga Km 7, Bahía Blanca, Argentina Dpto de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur. Bahía Blanca, Argentina, San Juan 670, Bahía Blanca, Argentina
Matias Maggi	Instituto de Investigaciones en Producción, Sanidad y Ambiente (IIPROSAM), CONICET, UNMDP, Centro de Asociación Simple CIC PBA, Mar del Plata, Argentina Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
Moustafa A. Sakr	Molecular Diagnostics and Therapeutics Department, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Egypt
Nirav Y. Bhatia	Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India
Pablo Giménez-Martínez	Instituto de Investigaciones en Producción, Sanidad y Ambiente (IIPROSAM), CONICET, UNMDP, Centro de Asociación Simple CIC PBA, Mar del Plata, Argentina Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina
Prachi M Pimple	Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India
Pijush K. Das	Infectious Diseases and Immunology Division, CSIR- Indian, Institute of Chemical Biology, Kol-kata 700032, India
Shalini Roy	Department of Biochemistry, University of Calcutta, Kolkata 700019, India
Sandra Churio	Departamento de Química, Facultad de Ciencias Exactas y Naturales, Instituto de Investigaciones Físicas de Mar del Plata (IFIMAR), CONICET, Universidad Nacional de Mar del Plata, Mar del Plata, Buenos Aires, Argentina
Sandra Fuselli	Instituto de Investigaciones en Producción, Sanidad y Ambiente (IIPROSAM), CONICET, UNMDP, Centro de Asociación Simple CIC PBA, Mar del Plata, Argentina Comisión de Investigaciones Científicas (CIC), Buenos Aires, Argentina
Tharanikkarasu Kannan	Department of Chemistry, Pondicherry University, Kalapet, Puducherry, 605014, India

CHAPTER 1**Monoclonal Antibodies as Therapeutic Agents for Inflammatory Diseases****Jéssica Bairos^{1,S}, Emanuel V. Capela^{1,S,*}, Ana P.M. Tavares¹ and Mara G. Freire¹**¹ CICECO – Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal

Abstract: Inflammation is a physiological process caused when an agent (chemical, biological or physical) transcends the primary defense barrier of an organism, setting a series of biological reactions to restore the integrity of such organism, thus playing a central role in the fight against those pathogens. Uncontrolled amplification of these events may lead to undesirable pathological manifestations such as cancer, diabetes, and cardiovascular, neurological, and chronic inflammatory diseases. Monoclonal antibodies (mAbs) were first described in 1975, and since then, they have proven to be relevant therapeutic agents in a myriad of diseases. The US Food and Drug Administration (FDA) has already approved more than 90 mAbs for the treatment of several diseases, from which approximately 26% were specifically approved for the treatment of inflammatory diseases, for instance, rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, psoriatic arthritis, and palmoplantar pustulosis. This chapter provides an overview of the inflammation process and main biochemical mechanisms, together with a vision on the current state of the art of the mAbs-based biopharmaceuticals market and their application as powerful therapeutic agents for inflammatory diseases.

Keywords: Biopharmaceuticals, Biopharmaceuticals Market, Biochemical Mechanisms, Inflammation, Inflammatory Diseases, Monoclonal Antibodies, Therapeutic Agents.

INTRODUCTION

Inflammation consists of the natural protective response of the body to injury. It occurs when an agent (chemical, physical or biological) transcends the primary defense barrier of the organism [1, 2]. It plays a central role in the fight against pathogens and can set biochemical reactions to restore homeostasis through the

* **Corresponding author Emanuel V. Capela;** CICECO – Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal; Tel: +351-234-401422, Fax: +351-234-370084; E-mail: emanuelcapela@ua.pt

^S Equal contribution

activation of specific components, which act through the destruction or isolation of the aggressor agent [3, 4]. Inflammation can be manifested as an acute process comprising three main events: i) increased blood flow, ii) development of edema, and iii) migration of leukocytes to the inflammatory focus [2]. Uncontrolled amplification of these events may lead to a chronic process, which is long-term and associated with the presence of lymphocytes fibrosis and tissue necrosis [5, 6]. This phenomenon causes undesirable pathological manifestations such as cancer, diabetes, and cardiovascular, neurological, and chronic inflammatory diseases [5, 6]. Therefore, this type of diseases' progression fostered the search for effective alternative therapies, which is a crucial objective to be achieved in the coming years.

In recent decades, technological advances in bioprocess engineering have increased the interest in the development of alternative therapies for inflammation treatment, particularly recurring to biopharmaceuticals [7]. Biopharmaceuticals are biological macromolecules or cellular components that can be used in vaccines or as therapeutic agents. They are obtained by biological processes (*in vitro* or *in vivo*) and are extracted from biological sources, for example, tissues and organs, microorganisms, fluids of animals, mammalian cell cultures, insects, and also plants [7]. The main examples include recombinant proteins (*e.g.*, monoclonal antibodies) and nucleic-acid-based products, which can be applied in the treatment of several inflammatory diseases, such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and palmoplantar pustulosis [8]. Among them, monoclonal antibodies are the most used biopharmaceuticals, representing 53% of all biopharmaceuticals approved [9].

Monoclonal antibodies (mAbs) were firstly described by Köhler and Milstein in 1975 [10], and since then, they have become the new backbone of the pharmaceutical industry as they have exquisite target selectivity and specificity [10]. mAbs offer the most promising prospects for new therapeutic approaches for inflammatory diseases [11, 12]. The most successful applications of mAbs are in autoimmune and inflammatory conditions [13]. Furthermore, as a wide range of mAb-based agents targets several cytokines, chemokines, adhesion molecules, receptors, and various types of cells, it is expected that these therapeutic “magic bullets” [14] will greatly expand in the future while providing better personalized treatment for a wide range of diseases. In this chapter, the most important aspects and main biochemical mechanisms of the inflammation process are overviewed, followed by a current review on the mAbs-based biopharmaceuticals market and approved mAbs product/therapies for inflammatory diseases. The action mechanisms and features of some relevant mAbs are also discussed, highlighting the advantages of mAbs-based therapies, together with the steps required for their increased adoption and widespread use.

MONOCLONAL ANTIBODIES

Structure and Properties of Antibodies

Antibodies, usually referred to as immunoglobulins (Igs), are glycoproteins found in plasma and extracellular fluids [15]. They are essential biomolecules in the immune-humoral system of all vertebrates [15], being the line of defense of the immune system [16]. They are produced naturally by specific plasma cells, namely the B lymphocytes, in response to exposure to “foreign” molecules or other antigens [15, 16]. In their composition, they present one or more regions, the paratopes, which recognize and bind to the epitopes of the antigen. This molecular recognition allows the neutralization and/or elimination of the antigen, allowing the organism to protect itself against the action of microorganisms and other harmful species, such as foreign proteins [17 - 19], carbohydrates [19], peptides [17], bacteria [17, 19], viruses [17], fungus [18] or even cancer cells [18]. As a result, an effective immune response takes place, often involving the production of a vast array of antibodies that are structurally similar yet unique, thus enabling the multiple epitope binding onto a given antigen [17, 20].

Independently of their specificity, all antibodies are heterodimer proteins structurally composed with four polypeptides chains – two identical heavy chains (H) and two similar light chains (L), in a “Y”-like shape form (Fig. 1) [15]. Disulphide bonds and non-covalent bonds are held together with chains by the “hinge” region, which provides stability and flexibility to the antibody. Furthermore, all polypeptide chains contain variable regions (V), presenting considerable variations in their amino-acid composition and where the antigen binds [17]. The constant regions (C), located at the carboxyl-terminal region, are specific for effector functions [17]. The antibody chains are further divided into L and H sections – each L chain has a variable domain (VL) and a constant domain (CL), while each H chain has one variable domain (VH) and three constants domains (CH1, CH2, CH3) [15, 17, 21], as shown in Fig. (1).

The antibodies may undergo proteolytic digestion, giving rise to new antibody fragments – Fab (**F**ragment **a**ntigen **b**inding) and Fc (**F**ragment **c**rystalline) [15]. Some enzymes can be highlighted in this topic: papain, for example, digests the antibodies into two Fab fragments and one Fc fragment, whilst pepsin cleaves the antibody below the disulphide bridge, generating an Fc fragment and a divalent F(ab') fragment [15]. The Fab fragment of the antibody contains the specific antigen-binding domain, and the Fc fragment is responsible for the effector properties, such as activation of natural killer cells, activation of the classical pathway of the complement system, and phagocytosis of the antigen [15].

CHAPTER 2

Pharmacotherapy of Emerging Antiviral Agents

Gaurav M Doshi^{1,*}, Hemen S Ved¹, Ami P Thakkar¹, Nirav Y. Bhatia¹ and Prachi M Pimple¹

¹ Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India

Abstract: Anti-infective agents have been one of the greatest accomplishments of modern medicine, which has led to a decrease in the number of deaths caused by various infectious diseases. The anti-infective agents are a broad family consisting of antimicrobials, antifungals, antimalarials, antiprotozoal, antituberculosis, and antiviral agents. Viral infections have caused millions of casualties worldwide, leading to the need for the development of effective antiviral agents. Although the replication mechanism differs significantly between the viruses, all viruses undergo steps like attachment, entry, genome replication, gene expression, and assembly for the release of the virions into the body of the host. Treatment with antiviral agents is essential for blocking the replication of the virus, and the currently available antiviral therapies are directed according to the disease. Furthermore, the treatment with antiviral agents aims to eradicate the viral pathogen from the host and prevent the clinical manifestation. Infectious diseases, such as human immunodeficiency virus (HIV), hepatitis B, and hepatitis C virus (HBV and HCV), and influenza, are of significant global concern. On the contrary, the outbreak of newer strains of influenza virus and Zika virus, Ebola virus, strains of coronavirus (CoV) like severe acute respiratory syndrome (SARS – CoV), Middle East respiratory syndrome (MERS – CoV) and novel Coronavirus (2019-nCoV) are life-threatening viral infections that exhibit major challenges to the humanity. As of date, multiple effective virostatics that target specific viral replication steps are approved for the treatment of viral infections. However, the use of such agents is restricted given the rapid emergence of antiviral resistance, which remains a major concern of current antiviral therapy. In this chapter, we summarize recent antiviral agents that show promising clinical benefits in various phases of clinical trials and also consider them as potential therapeutic agents in the future. Besides, we highlight and analyze the development of novel inhibitors targeting various stages of the viral life cycle that act by distinct mechanisms against current and emerging viral infections. Many antiviral drugs currently available are based on the concept of traditional chemotherapy. Nevertheless, new developments and advances in molecular biology have opened up possibilities to alternate treatment approaches. Clinical trials to evaluate gene silencing mediated by small interfering RNA (siRNA) and antisense RNAs expression against infection with a respiratory syncytial virus (RSV) have recently been initiated. Moreover, *in-vitro* studies of antisense RNA or siRNA

* Corresponding author Gaurav Doshi: Department of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, V. M. Road, Vile Parle (W), Mumbai, India; Tel: 9819771515; E-mail: gaurav.doshi@bncp.ac.in

technology have shown promising results in various virus strains. Despite the recent advancements, the development of targeted delivery of antiviral RNA molecules remains a major challenge since DNA viruses and retroviruses can incorporate their genomes into human genomes. To emphasize, antiviral drugs against particular target proteins have been effective in the treatment of prevalent infectious diseases such as HIV and HCV. Thereupon, broad-spectrum antiviral drugs instead of antivirals against specific virus infections need to be designed. With the rapid development of in-silico tools and gene modification strategies, antiviral drugs with better therapeutic index and safety profile will be developed against infectious diseases in the future. In fact, the effective design of newer antiviral drugs will reduce the possibility of emerging antiviral resistance.

Keywords: Antivirals, Clinical trials, Coronavirus, Human immunodeficiency virus, Middle East respiratory syndrome, Pharmacotherapy, Respiratory syncytial virus.

INTRODUCTION

Viral infectious diseases are of great concern as they cause significant morbidity and mortality in humans. To combat viral diseases, it is essential to constantly develop antiviral drugs and vaccines. Around 90 antiviral drugs have been approved in the treatment of the nine viruses that cause human infectious diseases, such as human immunodeficiency virus (HIV), human cytomegalovirus (CMV), hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex virus (HSV), influenza virus, respiratory syncytial virus (RSV), varicella-zoster virus (VZV) and human papillomavirus (HPV) [1, 2]. On the contrary, emerging and re-emerging viruses like Zika virus, Ebola virus, strains of coronavirus (CoV) like severe acute respiratory syndrome (SARS – CoV), Middle East respiratory syndrome (MERS – CoV), and novel coronavirus (2019-nCoV) exhibit major challenges to the humanity [3]. There is always a threat to the global health posed by drug-resistant virus strains, which can emerge because of the high mutation rates of RNA viruses. The primary focus in the past has been on virus targets, and this has proven to be a very effective approach. It is now being replaced by a different approach such that the strategies include compounds that target generic viral targets, such as RNA or DNA synthesis, which may be active against various viruses, as well as compounds that target host cellular activities needed for virus replication [4, 5].

Notably, toxic side effects limit the clinical use of currently approved antiviral drugs. In addition, antiviral chemotherapy has many specific drawbacks [6]. To begin with, selective antiviral drugs have a limited antiviral activity spectrum. Additionally, since antiviral drugs target the steps in viral replication, they are ineffective in the latent phases of certain viral infections. As a result, eradicating latent virus infections is currently not possible. Besides, antiviral treatment should

be started early to avoid permanent tissue damage. Timely treatment is highly unlikely without an early and precise diagnosis, which is difficult in the cases of many viral infections [1, 7]. Cross-resistance among antiviral drugs is the next major problem that must be addressed. Resistance to one drug is often associated with decreased susceptibility to another drug of the same class [8, 9]. Several approaches have been proposed to reduce resistance, including the use of combination therapy wherever possible, avoiding repeated use of antiviral drugs, and discontinuing the treatment whenever possible [10].

In this chapter, we give an overview of the major classes of antiviral drugs along with the development of novel inhibitors against current and emerging viral infections. To give a comprehensive overview, we highlight the most recent advances on antiviral drugs and their clinical perspectives against emerging infectious diseases.

EXISTING ANTIVIRAL CLASSIFICATION

5-substituted 2'-deoxyuridine Analogs

Many 5-substituted derivatives of 2'-deoxyuridine are used in the treatment of herpes virus-induced infections, whereas some derivatives inhibit the reproduction of the Poxviridae family viruses. Antiviral drugs like idoxuridine (5-iodo--'deoxyuridine), trifluridine (5-Trifluoromethyl-2'-deoxyuridine), and brivudine (5-(2-bromoethenyl)-2'-deoxyuridine) are a class of 5-substituted 2'-deoxyuridine analogues [11, 12]. Although these drugs fall under the same group, the mechanism of their action differs. Idoxuridine, trifluridine, and brivudine are chemically similar to thymidine that inhibits the replication of various DNA viruses, mainly herpesviruses and poxviruses [13, 14]. In turn, the phosphorylated derivatives interfere with various enzyme systems. The triphosphate prevents the synthesis of viral DNA and is incorporated into viral and cellular DNA. Likewise, brivudine is converted by thymidine kinases of HSV-1 and VZV to its monophosphorylated form and then by cellular kinases into diphosphorylated and triphosphorylated forms. The triphosphorylated form gets incorporated into the viral DNA, which, in turn, blocks the action of DNA polymerases and inhibits viral replication. Serious side effects associated with thymidine analogs are transient burning or stinging and corneal defects. Unlike idoxuridine and trifluridine, brivudine is less toxic and has a favorable safety profile [15 - 17].

Nucleoside Analogs

Nucleoside analogs are used in the treatment of various infections caused by HSV, HCMV, VZV, HIV-1, HBV, and HCV due to their high antiviral potency and significant pharmacokinetic parameters. Vidarabine (9- (β--

CHAPTER 3

Antiviral Activity of Vitamin D and COVID 19: Current Understanding

Mahmood A. Al-Azzawi^{1,*} and Moustafa A. Sakr²

¹ Department of Pathological Analysis Techniques, College of Medical & Health Technologies, Ahl Al Bayt University, Karbala, Iraq

² Molecular Diagnostics and Therapeutics Department, Genetic Engineering and Biotechnology Research Institute, University of Sadat City, Egypt

Abstract: Innate and adaptive immune responses, which are intimately related to the evolution of many infectious diseases, are influenced by the biologically active form of vitamin D. From a mechanical perspective, there are several rationales to assume that vitamin D positively modifies host responses to SARS-CoV-2, either in the early infection or subsequent hyper-inflammatory stages of COVID-19. It has been long known that vitamin D metabolites induce antiviral effects through indirect and direct mechanisms *via* antimicrobial peptides, immune modulation, the interaction between major viral and cellular particles, initiation of apoptosis and autophagy, and diversity of hereditary and epigenetic aspects. The remarkable overlap between the deficiency of vitamin D and risk factors for severe COVID-19, including obesity, aging, and Black or Asian ethnicity, has motivated researchers to assume that supplementation of vitamin D can be promising as a preventive or treatment agent for COVID-19. Since the outset of the pandemic, researchers have integrated literature searches and cross-sectional statistical studies to appraise the vitamin D level impact of COVID-19, whereby nearly 30 observational studies have confirmed that the incidence, severity, and mortality of COVID-19 are inversely related to the serum 25OHD concentrations. Also, some recently announced clinical trials indicated that vitamin D supplementation has a positive effect on the severity of COVID-19; however, other studies, including clinical trials, have not supported that, especially if we take into account what was revealed in a recent clinical trial, *i.e.*, airway diseases are related to the irregular metabolism of vitamin D increasing the potential of developing vitamin D deficiency due to pulmonary inflammation. Therefore, more dedicated studies are required without critical limitations to ascertain the actual effect of vitamin D in preventing and treating COVID-19, and if its effectiveness is proven, the effective dose must be determined.

* Corresponding author Dr. Mahmood A. Al-Azzawi: Department of Pathological Analysis Techniques, College of Medical & Health Technologies, Ahl Al Bayt University, Karbala, Iraq; Tel: 009647826002311; E-mail: mmahmood41@yahoo.com

Keywords: ACE2, ARDS, Antiviral, Betacoronavirus, Calcidiol, Calcitriol, Coronavirus-2, COVID-19, Epidemiological, Ethnicity, Inflammation, Innate, Mortality, Pandemic, RAS, RCTs, SARS-CoV-2, Severity, Vitamin D.

INTRODUCTION

In the past twenty years, seven coronaviruses have appeared, causing mild to severe respiratory diseases in humans, including Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) (a Betacoronavirus lineage B/Sarbecovirus). These were responsible for causing respiratory syndromes that may sometimes be very severe and may cause multi-organ failure with reverse myocardial remodeling, myocardial stress, and cardiomyopathy, which can be fatal, especially among children, elderly, patients suffering from chronic lung and hypertension diseases, and those who live in cities with high pollution levels [1 - 4]. In late 2019, the world witnessed the third prime epidemic of Coronavirus (CoV) infection, originating from Wuhan, China, and it was first called 2019-nCoV [1], and then it was renamed by the World Health Organization to COVID-19 in February, 2020. A novel coronavirus (SARS-CoV-2) is recognized as the causative agent of Coronavirus Disease 2019 (COVID-19), which represents one of the most critical epidemiological events that have represented the greatest threat to public health in the past hundred years [5]. In addition to the worsening of the socio-economic conditions caused by this pandemic, it paralyzed the economy and stalled life in most parts of the world [6, 7].

Coronaviruses are positive-strand RNA viruses and enveloped in a lipid bilayer with ca 30 kb in size. These viruses infect a wide range of birds and mammals and are usually carried through the respiratory pathway [8, 9]. Four major coronaviruses (NL63, OC43, 229E, and HKU1) and three extremely pathogenic zoonotic (SARS-CoV, MERS, and SARS-CoV-2) are categorized in humans. Severe atypical pneumonia is usually the immediate cause of death [10, 11]. Unfortunately, none of them has efficient anti-viral drugs [12 - 15], hence there is an urgent need for effective treatments. Seven vaccines are currently administered with more than 75% efficacy.

The pathophysiology of COVID-19 disease and the major reason for death is due to the increased inflammatory molecules (accompanied by immune cell infiltration, necrosis, and infected tissues hyperplasia), mainly at the lung level; this impairs the pulmonary oxygen interchange, causing severe pneumonia [16 - 18]. Several systemic alterations have also been perceived, especially in patients over the age of 60, which involve perturbation of normal levels of plasma of lactate dehydrogenase enzyme, C-reactive protein, platelet cells, and lymphocytes [19]. Interestingly, the elderly were more prone to die [20]. While indicators of

the prevalence of the virus and its severity are increasing with its arrival to new geographical zones, clinical trials are being conducted for some hopeful vaccines, taking into consideration that it may not take less time to obtain data on the extent of their efficacy and level of antibody protection [7, 21 - 23]. Thus, the existing options to confront COVID-19 disease and epidemics presently are based on (1) implementing a wide range of antivirals that can alleviate virus infection, (2) mitigation of acute inflammatory clinical symptoms, and (3) social distancing between the population, taking into account the precautionary measures in cases of necessary socialization to limit the increase in infections [21, 24]. In the aspect of the lack of a definite treatment against the COVID-19 deadly pandemic, its rapid development, and the direct effects of social isolation on the economic situation, particularly in developing countries, the necessity emerges to search about the existing and known pharmacological agents that boost or augment the performance of the immune cells.

SARS-CoV-2 appears to essentially use the alveoli macrophage escape mechanism, followed by a cytokine storm and hyper inflammatory molecules in critical patients [7], as a pathogenic process for the development of acute respiratory distress syndrome (ARDS) [25]. The spike protein of SARS-CoV-2 binds angiotensin-converting enzyme 2 (ACE2) of the pneumocystis type II cell receptor [26]. Patients with COVID-19 showed significantly elevated plasma angiotensin-2 levels, which were directly proportional to the viral load copies and severe lung injuries [27]. Thus, this indicates a strong link between the COVID-19 disease and the Renin-Angiotensin System (RAS). It is possible for SARS-CoV-2 to target both upper and lower lung host cells and start the infection by the attachment of the spike (S) protein to the receptor of ACE2 [28 - 32]. This receptor is a crucial enzyme for controlling the RAS that adjusts blood pressure and blood vessel homeostasis. Interestingly, it was found that patients with high blood pressure, coronary heart disease, diabetes, and cerebral vascular disease exhibit higher ACE2 mRNA expression, and this may co-relate the higher risk of deadly COVID-19 disease in these individuals [33, 34]. In addition, SARS-CoV-2 can also target the central nervous system cells *via* ACE2 receptors, indicating that this neurological mechanism is involved in disease severity and mortality [35]. It was recently demonstrated in hypertensive mice that in relation to the vitamin D/RAS interaction, ACE2/Ang (1-7)/MasR signaling cascade plays a role in vitamin D neuroprotective effects in the brain [36]; it was also observed that vitamin D leads a role of cofactor D in mitigating incident atrial fibrillation by inhibiting RAS [37]. Moreover, the re-adjustment of normal plasma levels of vitamin D [the major circulating form of vitamin D is calcidiol, 25-hydroxycholecalciferol, or 25-hydroxyvitamin D (abbreviated 25OHD)] in patients with vitamin D deficiency elicits peripheral RAS blockade [38]. In the hepatic cells, the exacerbated activation of RAS induces liver dysfunction and

Anti-infectives to Combat Leishmaniasis

Shalini Roy¹, Anindita Ukil¹ and Pijush K. Das^{2,*}

¹ Department of Biochemistry, University of Calcutta, Kolkata 700019, India

² Infectious Diseases and Immunology Division, CSIR- Indian Institute of Chemical Biology, Kolkata 700032, India

Abstract: Anti-infectives, by definition, refers to the drugs that can act against infection either by inhibiting the spread of infectious agents or killing them outright. These include a plethora of compounds that encompass antibiotics, anti-fungals, anti-helminthics, anti-malarials, anti-leishmanials, anti-protozoals, anti-tuberculosis, and antiviral properties. This chapter is dedicated to specifically focus on articles related to the anti-leishmanial therapeutics which entails drug development, techniques to improve drug delivery, and identification of new cost-effective better therapeutics which would have immense potential to overcome all the limitations of the present-day therapies. Leishmaniasis is a dreaded parasitic disease caused by the protozoan parasites of the genus *Leishmania*. It can be categorized into three types: cutaneous, mucocutaneous, and visceral, amongst which visceral leishmaniasis (VL) is a neglected tropical disease that results in significant morbidity and mortality worldwide. Approximately 500,000 new cases per year of visceral leishmaniasis (VL) are supposed to occur globally, of which 90% of the new cases are found to affect just five countries, including India. Therapeutic measures those in vogue, again pose a number of serious limitations related to toxicity, lengthy regime, drug side effects, drug resistance, and cost, making overall treatment a complex issue. Again, VL poses unique problems in different settings which is a major threat for the choice of treatment. Furthermore, fundamental differences in the behavior of the causative parasites and the response of the host to the pathogen in different settings may also vary which can complicate the choice of treatment. The healthcare provision for VL patients in India is not up to the mark as it is a poorly standardized system of private care, which is associated with relatively high costs, thus making treatment difficult for the poor population. This is especially a 'disease of the poor' mostly affecting the lower socio-economic population who is malnourished and cannot strictly abide by regular monitoring or follow-ups during treatment owing to poverty reasons. Drug resistance has become a growing limitation because the partially recovered patients has the possibility of developing parasites resistant to treatment due to insufficient drug dosage, which in turn gets transmitted to new patients causing primary drug resistance. To alleviate all these problems of current therapies encountered so far, it is a necessity of paramount importance to explore and develop new drugs that can enrich the known small armamentarium of anti-leishmanials. Discovering new chemotherapeutics that are

* Corresponding author Pijush K. Das: Infectious Diseases and Immunology Division, CSIR- Indian Institute of Chemical Biology, Kolkata 700032, India; Tel: 91-33-24140921; E-mail: pijushdas@iicb.res.in

cheap, effective, less toxic and capable to overcome drug resistance will help to better combat the disease. Available treatment options are quite limited, and planning to switch to combination therapy is also equally important, as it can scale up treatment efficacy. Overall, this chapter aims to highlight the challenges of the current anti-leishmanial therapies, coupled with the unraveling of the new therapeutic modalities and their mechanisms of action which potentiates them as better anti-leishmanial agents, thereby overcoming the problems of present-day therapeutics. Furthermore, it will also shed light on the importance of various immunomodulators and investigational drugs which might come up as effective, remedial therapeutics against leishmaniasis, in the future trials.

Keywords: Amphotericin, Anti-Leishmanial, Antimonials, Chemotherapy, Cutaneous Leishmaniasis (CL), Drug Delivery, Drug-Resistance, Immunomodulators, Miltefosine, Visceral Leishmaniasis(VL).

INTRODUCTION

This chapter is dedicated to focus is fine on the anti-infectives that can be characterized as anti-leishmanial by virtue of their potent leishmanicidal effects. The chapter provides a comprehensive understanding of the past and present anti-leishmanials being used, their growing limitations, and it also sheds light on elucidation of novel therapeutics that might have the potential to circumvent all the present-day challenges.

Leishmaniasis

Leishmaniasis, caused by the protozoan parasite *Leishmania*, is a group of diseases involving self-healing cutaneous to fatal visceral leishmaniasis. They are of three types, cutaneous, mucocutaneous, and visceral. Cutaneous leishmaniasis (CL) is characterized by skin lesions on the exposed parts of the body. Mucocutaneous leishmaniasis (MCL) causes the destruction of mucous membranes of the nose, mouth and throat. Both CL and MCL are not fatal and sometimes self-healing also. However, visceral leishmaniasis (VL) is the most dangerous form and is fatal if not diagnosed early and treated properly. VL particularly affects the organs in the viscera like spleen, liver and bone marrow. It is prevalent in tropical and subtropical countries, including India. As far as death from protozoal infections are concerned, this disease stands second only to malaria [1]. It is considered as neglected tropical disease.

Causative Parasite and the Vector

It is really surprising that although all three types of the disease are caused by morphologically very similar parasites of the genus *Leishmania*, they elicit such a strikingly different pathological response. Thus, CL is caused by *L. major* and *L. tropica*, MCL is caused by *L. braziliensis* and *L. mexicana* and VL is caused by *L.*

donovani. Infected dogs, human beings, or wild canids may act as reservoirs for transmission of the parasite through the bite of the insect vector *Phlebotomus argentipes*, *P. papatasi*, and *P. sergentis* commonly known as sandfly. *Leishmania* parasites exist in two forms, promastigote and amastigote. Promastigote is long (10-20 μm), tubular-shaped with a long flagellum, and resides in the gut of the sandfly vector. Amastigote is much smaller, ovoid-shaped (1-2 μm in diameter), contains no flagella, and resides in the macrophages of mammalian host.

Life Cycle

Leishmania parasites have a digenetic life cycle consisting of a mammalian host and an insect vector, sandfly. As described earlier, transmission of the parasite between mammalian hosts occurs by the bite of the sandfly vector. The digenetic life cycle involves three developmental stages, namely, procyclic promastigotes, metacyclic promastigotes, and amastigotes (Fig. 1) [2]. Amastigote is the infective form that replicates within host macrophages for its propagation.




Fig. (1). Lifecycle of *Leishmania donovani* between two hosts, insect vector sandfly and human, is depicted above.

Mode of Transmission

Promastigote form in the sandfly gut subsequently transforms into the infective

CHAPTER 5

Anthelmintic Drug Discovery: Current Situation and Future Perspectives

María Gabriela Blanco^{1,2}, María José De Rosa^{1,2,*} and Diego Rayes^{1,2,*}

¹ Laboratorio de Neurobiología de Invertebrados. Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB) CCT UNS-CONICET. Bahía Blanca, Argentina. Camino La Carrindanga Km 7, Bahía Blanca, Argentina

² Dpto de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur. Bahía Blanca, Argentina. San Juan 670, Bahía Blanca, Argentina

Abstract: Nematode parasites cause several neglected tropical diseases in humans such as lymphatic filariasis, onchocerciasis (river blindness), and soil-transmitted helminthiasis. Approximately 30% of the human world population is infected with at least one parasite and this prevalence could be even higher in rural areas and low-income countries. Although nematode infections are rarely lethal, they are associated with morbidity and severe consequences, particularly in children.

There are several concerns about the management and treatment of these diseases. Currently, the repertoire of nematocidal agents is limited, and these drugs are not 100% effective against all nematode parasitosis. In addition, the extensive use of these few drugs in massive administration campaigns in humans would probably lead to the development of resistance very soon. Further worsening the situation, the interest of the pharmacological industry in developing novel anthelmintics is low since these infections are mostly endemic in poor countries that do not constitute a profitable market. Under this alarming scenario, there is an urgent need to develop new and broad-spectrum antiparasitic drugs.

Traditional preclinical drug discovery is a long, expensive, and complex process. Thus, innovative strategies and alternative models, such as the free-living nematode *Caenorhabditis elegans*, are required to reduce costs and accelerate times. Its genetic amenability and the feasibility of performing high-throughput screening assays, convert this nematode into an excellent platform for nematocidal drug screening.

This chapter summarizes the current situation on antiparasitic drug discovery and discusses the use of *C. elegans* at the initial steps of drug development to accelerate the appearance of new drugs.

* **Corresponding author María José De Rosa and Diego Rayes:** Laboratorio de Neurobiología de Invertebrados. Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB) CCT UNS-CONICET. Bahía Blanca, Argentina. Camino La Carrindanga Km 7, Bahía Blanca, Argentina; Tel: +54-0291-4861201; Fax: +54-0291-4861200; E-mail: mjderosa@criba.edu.ar, and Instituto de Investigaciones Bioquímicas de Bahía Blanca (INIBIBB) CCT UNS-CONICET. Bahía Blanca, Argentina; Tel: +54-029-4861201; Fax: +54-0291-4861200; E-mail: drayes@criba.edu.ar

Atta-ur-Rahman (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

Keywords: Anthelmintic Drugs, *C.elegans*, Drug Development, Intestinal Infections, Neglected Diseases, Nematode Infections, Parasites, Tissue Infections.

INTRODUCTION TO PARASITIC NEMATODES

Parasitism is a form of ecological interaction, in which one member, the parasite, benefits from the use of resources gathered by another member, the host. In animals, the mechanisms for obtaining food have led to the development of predatory and parasitic ways of life. The predator feeds on another organism, the prey, usually hunted by himself and eventually killed. The parasite lives in biological association with another living being, the host, to ensure their own survival and reproduction. Generally, the predator is larger and more powerful than the prey; in contrast, the parasite is smaller and weaker than its host. Usually, parasites do not kill their hosts, but they can cause pathogenic actions by altering the homeostatic balance or the immune response.

Parasites are a heterogenous group of organisms divided into three main classes: protozoa (unicellular organisms that live inside or outside host cells), helminths (multicellular organisms that due to their size are solely extracellular pathogens) and ectoparasites (arthropods that live on the surface of the host's body). Helminths (from the Greek *helmins*, meaning worms) include two major phyla: nematodes (roundworms) and platyhelminths (flatworms that comprise cestodes (tapeworms) and trematodes (flukes)). Several bacteria, rickettsias, viruses and fungi can also be considered parasites. However, to facilitate systematization, the study of these biological agents has been separated into different disciplines: bacteriology (bacteria, rickettsias and spirochetes), mycology (fungi), and virology (viruses). Therefore, the term parasites generally refers to protozoa and metazoans (helminths and arthropods) that benefit at the expense of other organisms (the host).

Parasites infect a wide range of species, including humans, companion animals, livestock, and crops producing a devastating impact on human life quality and economy. Parasitic diseases are a health problem all over the world. Most parasitic diseases are endemic in under-developed countries, due to inappropriate sanitary and infrastructure conditions associated with poverty. However, tourism and migratory movements have spread some parasitic infections to non-endemic regions as well.

Helminths: Phylum Nematoda

Nematodes (from the Greek *nemat* "threads" and *odes* "like") or roundworms include around 25,000 species and constitute the third phylum of the Kingdom Animalia (behind the phylum Arthropoda and the phylum Mollusca) in number of

species, breadth of distribution, and amount of biomass. This group includes free-living non-parasitic members and parasitic species that infect plants, animals and humans causing important diseases such as filariasis, ascariasis, triquinellosis among others.

Nematodes are cylindrical worms, non-segmented, with tapering anterior and posterior ends and covered with a usually translucent, flexible acellular cuticle secreted by the hypodermis. Most of them are microscopic, such as *Trichinella spp.*, which is only a few mm long. However, some species such as *Ascaris spp.* can reach more than 30 cm long. They have simple anatomy, which includes digestive, reproductive, nervous and excretory systems. In contrast, nematodes do not have circulatory and respiratory systems. The digestive tract includes the foregut (stomodeum; buccal cavity and the muscular pharynx that pumps food through the gut), the midgut (intestine), and the hindgut (proctodeum; rectum and anus). Depending on their feeding habits, nematodes can contain specialized structures in their mouth. For instance, the parasitic nematode *Ancylostoma duodenale* contains tooth-like structures used to attach to the intestinal villi of the host [1]. Nematodes only have longitudinal body wall muscles. Synchronized dorsal and ventral contraction of these longitudinal muscles permits the typical back and forth thrashing movement of these worms. The nervous system consists of the nerve ring, a circumpharyngeal neuropil composed of neuronal processes whose cell bodies cluster in the head, and four longitudinal nerve cords that run along the length of the body in ventral, dorsal, and lateral positions.

Nematodes have well-developed reproductive systems adapted to produce large amounts of eggs. Most of them are sexually dimorphic, with females and males. However, some species can be hermaphrodites (*e.g.*, *C. elegans*) or parthenogenetic (parasitic females of *Strongyloides stercoralis*). The females lay eggs, usually after fertilization by males (in hermaphrodite individuals could also be by self-fertilization). Nematode eggs hatch into larvae (juvenile stages). Each larval stage finishes by a molt. All nematodes have four larval stages, with the first molt usually occurring in the egg. After the final molt, the nematodes differentiate into reproductive stages (hermaphrodites, males and females). Complete life cycles (from egg to egg) are generally short, ranging from four days (for the free-living *C. elegans*) to four-six weeks (for most parasite worms). When exposed to adverse conditions, several nematodes have the capacity of arresting their larval development. These arrested stages are generally non-feeding and can subsist on internal food stores for months until reencountering favorable conditions.

Overview of Nematode Infections

All species of vertebrates serve as hosts for parasitic nematodes. Some of these

Therapeutic Targets for Emerging Zika Virus Infection and Vaccines in Clinical Trials

Deepthi Ramesh¹, Balaji Gowrivel Vijayakumar¹ and Tharanikkarasu Kannan^{1,*}

¹ Department of Chemistry, Pondicherry University, Kalapet, Puducherry, 605014, India

Abstract: Zika virus is a mosquito-borne disease initially limited to sporadic cases in Africa and Asia. With the recent emergence of the Zika virus in Brazil in 2015, the virus rapidly spread throughout America. Even though most of the Zika virus infections have a mild influenza-like illness, severe manifestations were also observed, including Guillain-Barre syndrome in adults and microcephaly in babies born to infected mothers. Due to the severity of this disease, structural virologists quickly studied its different features. But, even with the elucidation of the viral genome, an effective treatment or suitable vaccine is not available for this disease so far. The viral vectors, pathogenesis, genetic diversity, and co-infection with other diseases remain unanswered. The production of an effective vaccine is hence a global health concern. This chapter discusses the emergence of the Zika virus and its detailed genome structure and replication cycle. The molecular pathogenesis and Zika viral therapeutics with detailed descriptions about the host and viral targets, investigational drugs, and vaccine candidates are explained here.

Keywords: Drug Discovery, Genome Structure, Host Protein Targets, Molecular Pathogenesis, Protease, RNA Polymerase, Vaccine, Viral Protein Targets, Zika Virus, Zika Virus Diagnostics, Zika virus Life Cycle.

ZIKA VIRUS DISCOVERY AND EPIDEMIOLOGY

Zika virus (ZIKV) is a positive single-stranded enveloped RNA virus in the *Flaviviridae* family and *flavivirus* genus. Dengue virus (DENV), Usutu virus (USUV), West Nile virus (WNV), Japanese encephalitis virus (JEV), Yellow Fever virus (YFV), and tick-borne encephalitis are other viruses that come under the flavivirus genus. Flaviviruses infect people from all around the world; 400 million people get infected per annum due to these viruses. ZIKV is transferred to humans through the infected bite of *Aedes* species mosquitoes, causing Zika fever with rashes, arthralgia, and conjunctivitis. Zika fever is often undetected or mis-

* Corresponding author Tharanikkarasu Kannan: Department of Chemistry, Pondicherry University, Kalapet, Puducherry, 605014, India; Tel:+91-413-2654411; Fax:+91-413-265 6740; E-mail:tharani.che@pondiuni.edu.in

taken as its symptoms are similar to other diseases like dengue fever or chikungunya [1]. Even after 60 years of its discovery in 1947, Zika fever was confined within African and Asian regions and was not regarded as a severe health threat until the early 21st century. However, in 2007, the ZIKV emerged again, leading to febrile illness in the Yap Islands of Federated States of Micronesia, and started a new chapter of ZIKV infections. Continuous ZIKV transmission in the Pacific islands (2014) and Brazil (2015) cemented that the virus had spread throughout the continent [1, 2].

In 1947, Kitchen, Dick, and Haddow initially identified the ZIKV from the serum of a sentinel monkey, Rhesus 766, from the Zika forest in Uganda, East Africa. The same team at the Virus Research Institute, Entebbe, Uganda, isolated the ZIKV from *Aedes africanus*, the vector for yellow fever virus, in 1948, providing the first evidence of human infection and confirming the *Aedes* species mosquitoes as the ZIKV vectors [3]. The clinical symptoms of ZIKV infection remained mysterious till scientist William Bearcroft auto inoculated with ZIKV and showed moderate symptoms like headache, fever, and nausea [4]. Amid a suspected yellow fever eruption in 1952, the first ZIKV human serum was isolated from a Nigerian girl. Also, two other patients showed a rise in serum antibodies against ZIKV [5]. In 1966, ZIKV was isolated from *Aedes aegypti* [6], and in 1977, Indonesia recorded the first human ZIKV infection in Asia [7]. However, for decades, ZIKV was considered as a mysterious virus with an unclear impact on the human population. In 2007, the first human transmission of ZIKV was identified outside of Asia and Africa. The Zika upsurge in an isolated island of Yap, Western Pacific, had 49 confirmed cases and 59 suspected infection cases with an additional 73% population having antibodies [8]. In 2008, two USA scientists who returned from southeast Senegal showed ZIKV infection-like symptoms, such as rashes, fatigue, headache, arthralgia, and one person was affected with haematospermia. One patient's wife became sick with no travel history but with similar symptoms. As ZIKV were identified in the semen samples, ZIKV transmission through sexual contact or body fluids was established [9]. In 2010, specimens from a child in Cambodia showed ZIKV infection, and in 2012, blood samples of a boy from the Philippines also tested positive for ZIKV infection [9]. During 2013 - 14, the eruption of ZIKV infection in French Polynesia was reported, with roughly 300 confirmed and over 19,000 suspected cases with Guillain-Barré syndrome (GBS) [10]. In Indonesia, during a dengue virus upsurge in 2014, one positive case of ZIKV infection was also detected, and from the infected person, many travelers from Thailand who visited Indonesia acquired ZIKV infections [9]. In 2014, New Caledonia reported an outbreak, and ZIKV sequence analysis marked two significant lineages, African and Asian. In 2015, 24 patients showed illness with rash, arthralgia, and conjunctivitis in Camaçari, Brazil. The identification of ZIKV RNA in seven

patients' serum confirmed the escalation of ZIKV in continental South America. Three patients had chikungunya RNA in serum, highlighting that Zika fever cannot be diagnosed with only clinical characteristics [8]. After the first reported cases, by 2016, Zika became an epidemic in Brazil, with microcephaly identified in children born to infected women. Phylogenetic analysis of ZIKV sequences from Brazil exposed the Asian lineage of the virus, which could have been introduced from the Pacific Islands in the 2014 FIFA World Cup or IVF World Sprint Championship. ZIKV was named a public health emergency of international concern (PHEIC) by WHO in February 2016 and later this status was withdrawn in November 2016. Singapore and Vietnam reported two outbreaks in Asia, and Thailand reported boundless transmission [11]. With 48 countries in the Western Hemisphere infected with ZIKV transmission by 2017, ZIKV became endemic in American regions, Southeast Asia, Central Africa, and the South Pacific [10]. Till now, 86 countries and territories have recorded ZIKV infection [12]. The significant events and timeline of ZIKV infections are given in Fig. (1).



Fig. (1). Significant events in Zika virus infection.

One factor involved in the rise of ZIKV strain in recent years with increased transmission potential and virulence can be attributed to the virus's genetic mutations because of the error-prone nature of viral polymerase. The factors like universal, demographic, technological, and social tendencies of population

Agro-Industrial Waste: New Source of Raw Material for the Control of American Foulbrood in Honey Bees

Pablo Giménez-Martínez^{1,2}, Cristina Ramírez³, Azucena Iglesias^{1,2}, Florencia Fangio⁴, Sandra Churio⁴, Matias Maggi^{1,2} and Sandra Fuselli^{1,5}

¹ Instituto de Investigaciones en Producción, Sanidad y Ambiente (IIPROSAM), CONICET, UNMdP, Centro de Asociación Simple CIC PBA, Mar del Plata, Argentina

² Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina

³ Departamento de Química y Bioquímica, FCEyN, Universidad Nacional de Mar del Plata, Argentina

⁴ Departamento de Química, Facultad de Ciencias Exactas y Naturales, Instituto de Investigaciones Físicas de Mar del Plata (IFIMAR), CONICET, Universidad Nacional de Mar del Plata, Mar del Plata, Buenos Aires, Argentina

⁵ Comisión de Investigaciones Científicas (CIC), Buenos Aires, Argentina

Abstract: Agro-industrial waste production represents an environmental problem, and its processing results in the obtainment of by-products that are rich sources of bioactive compounds. *Apis mellifera* are social insects that create the ideal conditions for the transmission of pathogens. American foulbrood (AFB) is the main pathology that affects bee brood; the causative agent is the Gram-positive bacteria *Paenibacillus larvae*. During the last years, there have been significant losses of hives by the use of synthetic antimicrobials for the control of AFB. The presence of antibiotics in honey and other products of the hive have generated concern in consumers regarding the risks of toxicity, negatively influencing the time of marketing and export. On the other hand, there is the possibility of the appearance of resistance by pathogenic microorganisms caused by incomplete treatments or an overdose of the antibiotic used. More than 70 plant extracts have been evaluated *in vitro* and *in vivo* against *P. larvae*; for this reason, the revaluation of biological waste material from agroindustry is being studied through pharmacodynamic and pharmacognosy analysis both in *P. larvae* and in the different stages of development of *A. mellifera*.

Therefore, this chapter proposes to investigate: (1) the effect of the application of fertilizer treatment on the hop cultivar in the composition and amount of secondary

* **Corresponding author Sandra Fuselli:** Instituto de Investigaciones en Producción, Sanidad y Ambiente (IIPROSAM), CONICET, UNMdP. Centro de Asociación Simple CIC PBA, Mar del Plata, Argentina and Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina; Tel:(0054223) 4268051; E-mail: beedarian@gmail.com

Atta-ur-Rahman (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

metabolites, (2) the bioactivity of extracts of hop leaves against *P. larvae*, and *in vitro* toxicity in larvae and adult bees, and the effect on genes of the immune system of bees.

Keywords: Agro-Industrial Waste, American Foulbrood, Antimicrobial Activity, *Apis Mellifera*, Flavonoids, Honey Bee, *Humulus lupulus*, *Paenibacillus Larvae*, Phenolic Compounds, Saponins, Secondary Metabolites.

INTRODUCTION

Bees of the species *Apis mellifera* L. (Order Hymenoptera) are social insects that make up colonies of more than 50.000 individuals, generating the ideal conditions for the transmission of pathogens [1]. The most important diseases that affect bees are American foulbrood (AFB), European foulbrood, Nosemosis and Varroosis, which can affect adult bees, larvae or both stages [2, 3]. *Apis mellifera* is responsible for pollinating 77% of the plant species responsible for the production of food resources that sustain the world population; due to this, they play an important role on society not only for the commercial products of the hive but also for contributing to the balance and proper functioning of ecosystems, and consequently to biodiversity. They are insects that provide significant environmental services due to their performance as biological indicators and pollination [4]. The current beekeeping production is negatively influenced by the diseases that affect the colonies that generate high mortality, and therefore, decrease the productive yield.

American Foulbrood

Characteristics of the Disease

This disease negatively affects *A. mellifera* during the larval stage; adult bees are asymptomatic passive or active carriers, being able to remain latent and appear suddenly due to stress factors, external conditions, genetic resistance or unknown causes [5]. It is recognized as the most destructive and widespread of all bacterial diseases of bee brood that not only kills the larvae but is potentially lethal to infected colonies. This disease is within the OIE Terrestrial Animal Health Code, and member countries are required to declare it.

Paenibacillus Larvae, the Causal Agent

The disease is generated by Gram-positive bacteria, rod-shaped (2.3 to 5 μm long by 0.5 to 0.7 μm wide), grouped in pairs, alone or in short chains, measuring 1.3 μm x 0.6 μm and mobile with flagella. Its main characteristic is the possibility of forming spores, which can be ellipsoidal, central or terminal, with high tolerance to high temperatures, and resistance to the action of chemical disinfectants, such

as chlorine, iodine-based products and ultraviolet radiation. The spores can remain infective for more than 40 years, being responsible for the beginning of the disease cycle [6 - 8] and only infect larvae of the genus *Apis* [9].

PCR analysis showed four genotypes of *P. larvae* ERIC (I-IV), showing that the resulting classification correlates with phenotypic differences [7]; the latest studies by Beims, Bunk [10] revealed a new genotype, *P. larvae* ERIC V.

Pathogenesis and Symptoms

The spores enter the interior of the hive through foraging bees, bees from infected hives, contaminated beekeeper tools, by the introduction of pictures with infected offspring, through feeding with contaminated honey and any exchange of material from diseased hives. Once inside the hive, the spores are brought to the brood by the nurse bees along with the food. The larvae ingest these spores that adopt their vegetative forms, given the appropriate conditions they have in the intestine, such as pH and percentage of oxygen. When the larva reaches its pre-pupal stage, the bacteria that have not yet been eliminated in the feces migrate, entering the endothelial cells of the intestine thanks to their flagella, reach the hemolymph and reproduce until they cause death due to generalized septicemia [2, 6, 11]. After several days, the pupa dries up and gradually acquires an increasingly darker coloration due to the pigmentation of *P. larvae*, being called at this stage as “scale” having a very high infective power, and may contain up to 2.5 billion spores, being a very important source of their dissemination [12].

Disease Control

Due to the characteristics of the disease, once AFB is detected in a region, it is very unlikely that it can be eradicated. Any of the methods mentioned below must inevitably be complemented with an intensive program of periodic inspections of the apiaries, within a maximum interval of 90 days, including the winter season. It is important to consider that if a single colony is left in the field untreated, it can destroy the work of several years of control.

Conventional Chemotherapy Treatment

This disease causes severe economic damage to the beekeeping sector in many honey-producing countries, because the presence of antibiotics in honey and other beehive products has generated concern in consumers regarding the risks of toxicity, negatively influencing the moment of its commercialization and export [8]. Likewise, there is the possibility of the appearance of resistance by pathogenic microorganisms, caused by incomplete treatments or an overdose of the antibiotic used.

SUBJECT INDEX

A

Acid(s) 280, 332
 boronic 280
 hydroxycinnamic 332
 Action 108, 305
 anti-inflammatory 108, 305
 antioxidant 305
 Activation 15, 284
 immune complex-mediated 15
 innate immunity 284
 Activity 26, 58, 62, 77, 82, 106, 108, 109,
 110, 182, 187, 189, 195, 196, 197, 227,
 233, 330, 331
 anti-leishmanial 195
 anti-pathogen 182
 fungicidal 331
 hemolytic 331
 immune 109
 immunomodulatory 108, 196, 197
 pangenotypic 82
 Acute 23, 28, 102, 103, 113, 116, 136, 140,
 144
 respiratory distress syndrome (ARDS) 23,
 28, 102, 103, 116, 136, 140, 144
 viral respiratory infections (AVRIs) 113
 Acyclic nucleoside phosphonate (ANP) 60
 Adenoviruses 62
 Agranulocytosis 229
 Airways lymphocytes 108
 Alanine aminotransferase 180
 Amphotericin B lipid complex (ABLC) 183
 Antileishmanial 188, 189, 190
 activity 188, 189
 efficacy 190
 Anti-leishmanial(s) 174, 175, 180, 186, 191,
 192, 195, 196, 197, 199
 agent 191
 drugs 180, 191, 192, 195
 therapeutics 174
 Antimicrobial 101, 109, 301, 303, 317, 322,
 324, 329, 330, 333, 334

activity 301, 303, 317, 322, 324, 329, 330,
 334
 peptides 101, 333
 proteins 109
 Antiparasitic drugs 186, 243
 Antiretroviral 81, 87
 therapy 81
 drug development 87
 Antiviral activity 58, 59, 66, 67, 76, 79, 80,
 86, 113, 282
 broad-spectrum 79
 Apoptosis 17, 33, 71, 101, 231
 Arthritis 1, 2, 30, 31, 33, 269
 psoriatic 1, 2, 30, 31, 33
 Ascariasis 211, 213, 215, 221, 228, 233
 Ascaris lumbricoides life cycle 214
 Aspartate aminotransferase 180
 Assays 78, 209, 241
 performing high-throughput screening 209
 Asthma 23, 31, 107, 108, 147
 eosinophilic 31
 ATPase activity 275
 ATP 275, 331
 hydrolysis 275
 synthase 331
 Autophagy 101, 281
 blocking ZIKV-mediated 281

B

Biosynthetic pathways 186, 304
 Blood transfusion 267
 Broad-spectrum anthelmintic activity 243

C

Cancer 1, 2, 20, 24, 27, 29, 34, 39, 117, 147,
 148, 185
 colorectal 148
 invasive lung 117
 metastatic breast 29, 147, 185
 urothelial 29

Atta-ur-Rahman (Ed.)

All rights reserved-© 2021 Bentham Science Publishers

- white blood cells 34
 - Cardiotrophin-like cytokine (CLC) 22
 - Case fatality rate (CFR) 116, 117
 - Castleman's disease 25, 26, 30
 - Cellular thymidylate kinase 59
 - Cellulitis 32
 - Cervical cancers 71
 - Chemotherapy 33, 55, 56, 175, 177, 197, 238
 - antiviral 56
 - traditional 55
 - Chikungunya virus infections 269
 - Chronic 24, 84, 85, 109, 112, 141
 - hepatitis B (CHB) 84, 85
 - kidney disease (CKD) 141
 - obstructive pulmonary disease (COPD) 24, 109, 112
 - Clathrin-mediated endocytosis 265
 - CMV 64
 - disease 64
 - infection 64
 - Complement-dependent cytotoxicity (CDC) 4, 223
 - Congenital Zika syndrome (CZS) 283, 284, 286
 - Conjunctivitis 260, 261
 - Coronavirus 27, 55, 56, 102
 - disease 27, 102
 - novel 55, 56, 102
 - Corticosteroid 107, 237
 - drugs 107
 - therapy 237
 - Coughing 27, 135
 - COVID-19 101, 102, 103, 111, 112, 113, 114, 115, 116, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 131, 132, 134, 143, 144, 146, 149, 150, 151, 152
 - cases 119, 120, 121, 123, 124, 125, 129
 - deaths 114, 119, 125
 - disease 102, 103, 111, 116, 126, 132, 134, 144
 - infection 115, 116, 118, 120, 122, 127, 128, 146, 149, 150, 152
 - pandemic 124
 - Crohn's disease 1, 2, 8, 25, 30, 31, 33
 - Cryo-EM structure of immature Zika virus 265
 - Cryopyrin-associated periodic syndrome 31
 - Cutaneous leishmaniasis (CL) 3, 175, 178, 183, 184, 185, 186, 188, 192, 198, 199
 - lesion 198
 - Cytokines 14, 22, 28, 32, 84, 107, 110, 112, 113, 195
 - disease-resolving 195
 - inflammatory 14, 28
 - polypeptide 22
 - pro-inflammatory 22, 32, 110, 112, 113
 - selgantolimod-induced 84
 - smooth muscle cells 107
 - Cytoplasmic 14, 61
 - membranous factories 61
 - sensors 14
- D**
- Dendritic cells 13, 37, 69, 107
 - Dengue virus 104, 110, 113, 115, 260
 - Diarrhea 36, 58, 61, 62, 63, 216, 218, 221, 226, 227, 232
 - Diffuse large B-cell lymphoma (DLBCL) 29, 30, 31, 33, 34
 - Diseases 29, 65, 102, 103, 109, 116, 147, 199, 210, 232
 - cardiovascular 109, 116
 - celiac 147
 - cerebral vascular 103
 - coronary heart 103
 - denovirus 65
 - hypertension 102
 - parasitic 210, 232
 - sickle cell 29
 - transmitted 199
 - Disorders 26, 29, 30, 32, 36, 37, 38, 40, 75
 - chronic inflammation 37
 - immune complex 75

inflammatory 32, 37, 38, 40
 Disposal systems 217
 DNA 56, 57, 58, 60, 63, 70, 71, 197, 284
 polymerases 57, 58, 60, 63, 71
 replication 70
 vaccines 197, 284
 viruses 56, 57
 DNA synthesis 56, 58, 61
 diphosphate blocks 61
 Downregulation 104, 284
 Drugs 25, 26, 111, 179, 186, 187, 192, 198,
 199, 233, 234, 238, 239, 274, 275, 276,
 287
 disease-modifying antirheumatic 25, 26
 endocrine 111
 first-line anti-leishmanial 179
 for neglected diseases initiative (DNDi)
 187, 192, 233
 targets 198, 238, 274, 275, 276, 287
 therapy 199
 transport 239
 treatment 186, 233, 234
 Dysregulation 25

E

Ebola virus 29, 55, 56
 infection 29
 Edema 2, 10, 222, 224, 269
 Electron microscopy 331
 Elephantiasis 222, 227
 ELISA 270, 271
 Embryogenesis 236, 240
 Encephalopathy 60, 230, 232
 Energy metabolism 330, 331
Enterobius vermicularis 212, 213, 215, 221,
 228, 229, 232
 Enzymes 3, 4, 19, 20, 27, 58, 62, 67, 102, 103,
 106, 149, 186, 187, 188, 283, 306, 314
 angiotensin-converting 27, 103
 dihydroorotate dehydrogenase 283
 lactate dehydrogenase 102

myeloperoxidase 20
 nitroreductase 187
 purine salvage pathway 188
 viral DNA polymerase 58
 viral helicase-primase 67
 Eosinophils 4, 15, 108
 Epidemic ZIKV strains 263
 Epididymitis 227
 Ergosterol pathway 186
Escherichia coli 9, 198
 Exocytosis 11, 21, 27, 266
 Eye 36, 224
 lesions 224
 protrusion 36
 worm 224

F

Fatal encephalopathies 236
 FDA 28, 62
 approved integrase inhibitors 62
 for severe life-threatening cytokine release
 syndrome 28
 Fibrosis 10, 104, 138, 142, 222
 chronic lymphatic vessel 222
 pulmonary 104
 Flavivirus infection 276
 Functions 4, 5, 6, 7, 10, 12, 14, 16, 19, 24, 62,
 105, 106, 135, 277
 immune respiratory system 105
 modulate NF- κ B 14
 neutrophil 16, 24

G

Gastrointestinal 63, 184, 226, 228
 discomfort 184
 function 63
 symptoms 226, 228
 toxicity 63
 Glucocorticoids 232
 Glutamate synthase 314

G-protein-coupled receptors (GPCRs) 11, 12, 17, 20, 21, 233
Granulocyte-macrophage 108
 colony-stimulating factor (GM-CSF) 108
Guanylyltransferase 276
Guillain-Barré syndrome (GBS) 261, 269, 284

H

Haemospermia 261
HBV 58, 60, 83, 86, 87
 infections 58, 60, 83, 86, 87
 replication 58
Helminthiasis 209, 237, 239
 soil-transmitted 209
 treatment 239
Hematospermia 269
Hemorrhage 34, 35
 conjunctival 35
Hepatic impairment 66
Hepatitis 55, 56, 57, 61, 62, 83, 84, 85, 86, 113
 B virus (HBV) 55, 56, 57, 84, 86
 C virus (HCV) 55, 56, 57, 61, 62, 83
 quantitative 84
Hepatomegaly 177
Herpesviruses 57, 61
High-throughput screening (HTS) 209, 241, 242, 243
Hippo signalling pathway 332
HIV 58, 61
 protease inhibitors 61
 reverse transcriptase enzyme 58
Hodgkin lymphoma 30
Human 8, 24, 26, 32, 55, 56, 59, 61, 71, 79, 80, 81, 113, 118, 146
 anti-human antibodies (HAHAs) 8
 cytomegalovirus 56
 immunodeficiency virus (HIV) 24, 26, 32, 55, 56, 59, 61, 79, 80, 81, 113, 146
 papillomavirus 56, 71
 respiratory syncytial virus (HRSV) 118

Hybridoma technology 7, 8
Hypercalcemia 147, 148
Hypercytokinemia 110
Hypergammaglobulinemia 177
Hyperparathyroidism 117
Hyperplasia 23, 102
 infected tissues 102
Hypertension 27, 61, 116, 120, 146

I

Immune system 3, 11, 17, 20, 21, 22, 24, 105, 106, 111, 333, 334, 335
 cells 24, 106
Immunity, cell-mediated 6, 286
Immunoliposome 189
Immunosuppression 27, 193
Infection(s) 15, 22, 23, 26, 27, 61, 63, 84, 105, 109, 103, 113, 146, 150, 181, 210, 213, 214, 216, 220, 221, 222, 225, 226, 270, 230, 236
 adenovirus 63
 antibody-dependent 15
 chikungunya 270
 cytomegalovirus 63
 fungal 146, 181, 222
 lymphatic filariasis 230
 microbial 105, 109
 oral 214
 parasitic 210, 225
 syndrome 226
 symptomatic 236
 urinary tract 84
Inflammatory 11, 17, 19, 20, 23, 24, 28, 37, 39, 108, 224, 237
 process 20, 24, 37, 39
 reaction 19, 224
 response 11, 17, 23, 28, 108, 224, 237
Influenza 55, 56, 105, 110, 112, 115, 118, 146, 149, 151
 virus 55, 56
Inhibitors 186

sterol biosynthesis 186
sterol synthesis 186
Insomnia 62, 305
Integrin-mediated cell adhesion receptor 13
Intestinal 210, 213, 220, 221, 233
 infections 210, 213, 220, 233
 inflammation 221
 nematode diseases 221

J

Japanese encephalitis virus (JEV) 260, 285, 286

L

Lactic acidosis 61
Larvicidal properties 273
Leishmania 175, 176, 187, 190, 193, 196, 197, 199
 antigens 197
 donovani 176
 infections 197, 199
 parasites 176, 187, 190, 193, 196
 protozoan parasite 175
Leishmaniasis 175, 179, 182, 187
 mucocutaneous 175
 therapy of 179, 182, 187
Leptospirosis 271
Leucyl amino peptidase 198
Leukemia inhibitory factor (LIF) 22
Levamisole-sensitive AChR (LACHR) 229
Lipophilicity 330
Liposomes 182, 189, 190, 193
 coating 193
Liver 103, 180
 damage 180
 dysfunction 103
Lower 76, 77, 86
 limit of quantification (LLOQ) 86
 respiratory tract infection (LRTI) 76, 77
Lung structure integrity 108

Lymphatic filariasis (LF) 209, 222, 223, 227, 230, 235, 237, 238, 243
Lymphedema 227
Lymphocytes fibrosis 2
Lymphoma 33

M

Macrocyclic Lactones 227, 229
Macular edema, diabetic 34, 35, 36
Malabsorption 144, 215
 syndromes 144
MAP-kinase pathways 14
Micronutrients 149, 150, 212, 304
Minimum inhibitory concentration (MICs) 317, 318, 319, 322, 325, 326, 327, 328, 330
Mitochondrial inner membrane protein 196
Mitogen-activated protein kinase (MAPK) 14, 17
Monophosphate dehydrogenase 282
Myeloma cells 25
Myelosuppression 60
Myocarditis 182

N

Neglected tropical diseases (NTDs) 192, 209, 212, 243
Nematode(s) 209, 210, 211, 212, 213, 214, 215, 216, 222, 227, 228, 229, 232, 238, 239, 240, 242, 243
 growth medium (NGM) 240
 infections 209, 210, 211, 212, 213, 214, 238, 243
 intestinal 212, 214, 215, 228
 parasitosis 209, 222, 238
Neoplastic transformations 20
Nephrolithiasis 61
Nephrotoxicity 60, 61, 63, 182
Neuromuscular junction 231, 233

Neuromyelitis optica spectrum disorder 26, 29, 31, 37, 39
NOD-like receptors (NLRs) 14, 15
Non-Hodgkin lymphoma 30
Non-nucleoside RNA polymerase inhibitor 278
Nucleic acid synthesis 330
Nucleoside reverse transcriptase inhibitors (NRTIs) 58, 59
Nutritional deficiencies 216

O

Onchocercomas 223, 224
Open reading frame (ORF) 263, 265
Osteoporosis 29, 146
Oxidation, fatty acid 180
Oxygen therapy 120

P

Parasitemia 191
Parasite protein 193
Parasitosis 219, 220, 222, 234, 238, 241
Pathogenicity 285, 286
Pathway 14, 27, 28, 104, 230, 277
 arachidonic acid 230
 endosomal 27
 excessive signaling 28
Peripheral 61, 83
 blood mononuclear cells (PBMCs) 83
 neuropathy 61
Phagocytosis 3, 4, 6, 15, 16, 19, 20, 190
 antibody-mediated 15
Pneumonia 32, 60, 105, 107, 116, 117, 140, 146
 community-acquired 105, 117, 140
Pneumonitis 221
Polyprotein processing 275
Positron emission tomography 34
Post-herpetic neuralgia (PHN) 73, 74
Principal component analysis (PCA) 309, 311, 312, 314

Processes 15, 211, 305, 315
 agricultural production 305
 fertilization 315
 immune complex-mediated inflammatory 15
 neuronal 211
Processing 59, 275
 metabolic 59
 proteolytic 275
Prognosis 111, 114, 136
Proteases 27, 61, 62, 195, 260, 275, 279, 280
 cysteine 195
 inhibitors 61, 62, 279, 280
Protein(s) 13, 15, 85, 275, 285, 314
 cytoplasmic 13, 15
 dsRNA-binding 85
 helicase 275
 synthesis 285, 314
Psoriasis 31, 33
 erythrodermic 33
 psoriatic 31

R

Reactions, systemic inflammatory 231
Reactive 11, 20, 151, 196
 nitrogen species (RNS) 20
 oxygen species (ROS) 11, 20, 151, 196
Renin 102, 103, 104, 135, 140, 150, 151
 angiotensin system (RAS) 102, 103, 104, 135, 140, 150, 151
 genes regulations 104
 synthesis 104
Respiratory 55, 56, 59, 75, 76, 77, 78, 102, 105, 111, 112, 113, 115, 116, 148, 151, 151
 infections 105, 111, 112, 113, 115, 116, 151
 syncytial virus (RSV) 55, 56, 59, 75, 76, 77, 78
 syndrome 55, 56, 102
 tract infections (RTIs) 77, 148
Reverse transcriptase enzyme 59

Rheumatoid arthritis (RA) 1, 2, 25, 26, 30, 31, 32, 37, 39, 146, 147
RNA-induced silencing complex (RISC) 85

S

Secondary metabolites (SM) 301, 304, 306, 307, 313, 314, 315, 324, 330, 331, 332, 333, 334
Signaling pathways 241
Skin 32, 175, 224, 227
 disease 32
 inflammation 227
 lesions 175, 224
Sodium antimony gluconate (SAG) 196
Soil-transmitted helminths (STH) 213, 214, 228, 233, 237, 243
Steroid hormone 105
STH infections 213, 215, 216, 228, 237
Stress 102, 109, 150, 240, 318, 331
 myocardial 102
 oxidative 109
Strongyloides stercoralis infection 237
Strongyloidiasis 213, 218, 221, 234
System 182, 214
 liposomal drug delivery 182
 lymphohematogenous 214

T

Target 2, 61, 186
 allosteric sites 61
 chemotherapeutic 186
 mAb-based agents 2
Therapy 9, 10, 33, 85, 174, 177, 185, 186, 187, 188, 196, 197, 235, 238
 immunomodulating 33
Thrombocytopenia 75, 177, 269
Thyroid-stimulating hormone receptor (TSHR) 36
Tissue 2, 10, 28, 228
 helminthiases 228

 necrosis 2, 10, 28
Toll-like receptors (TLRs) 13, 15, 83
Translation efficiency 284
Transmembrane 16, 25, 70,
 glycoproteins 70
 receptors 16, 25
Treating Zika Virus Infection 277
Treatment 26, 37, 236
 trichinellosis 236
 of neuromyelitis optica spectrum disorder 26, 37
Triquinellosis 211
Tuberculosis sepsis 32
Tumor necrosis factor (TNF) 16, 17, 18, 22, 24, 110

V

Vaccine therapy 197
Varicella-zoster 56, 57, 59, 60, 66, 73
 immune globulin (VZIG) 59, 60
 virus (VZV) 56, 57, 59, 60, 66, 73
Vascular endothelium growth factor (VEGF) 25, 34
Vector-transmitted diseases (VTD) 215
Vero cells 285
Viral 56, 57, 58, 59, 60, 61, 62, 66, 71, 73, 86, 105, 110, 112, 150, 260, 270, 274, 275, 274, 275, 277, 279, 285, 287
 culture-based techniques 270
 DNA 57, 58, 59, 62, 66
 infections, respiratory 150
 infectious diseases 56
 proteins 62, 73, 86, 274, 287
 replication 56, 57, 60, 61, 71, 73, 105, 110, 112, 275, 277, 279, 285
 targets 260, 275
Virus 27, 55, 56, 59, 60, 62, 70, 103, 109, 110, 115, 151, 260, 261, 262, 263, 267, 274, 277, 285, 287, 331
 herpes 62
 pathogenic 277

respiratory 115
replicating 285
sarcoma 331
infections 56, 103, 274
Visceral leishmaniasis infection 177
Vitamin D endocrine system (VDES) 144

W


West Nile virus (WNV) 260, 280, 286

Y

Yellow fever virus (YFV) 260, 261, 286

Z

Zika 260, 261, 262, 267, 268, 269, 270, 271,
277, 279, 280, 282, 283, 284, 285
fever 260, 261, 262
infection 261, 262, 267, 268, 269, 270, 271,
277, 279, 280, 282, 283, 284, 285
transmission 261, 262, 268, 271
vaccine 283, 284
Zika virus
structural proteins 274
transmission 267
vaccine 283



PROF. DR. ATTA-UR-RAHMAN, *FRS*

Prof. Atta-ur-Rahman, Ph.D. in Organic Chemistry from Cambridge University (1968) has 1,232 international publications (45 international patents and 341 books). He received the following awards: Fellow Royal Society (FRS) London (2006), UNESCO Science Prize (1999), Honorary Life Fellow Kings College, Cambridge University (2007), Academician (Foreign Member) Chinese Academy of Sciences (2015), Highest Civil Award for Foreigners of China (Friendship Award, 2014), High Civil Award Austria ("Grosse Goldene Ehrenzeischen am Bande") (2007), Foreign Fellow Chinese Chemical Society (2013), Sc.D. Cambridge University (UK) (1987), TWAS (Italy) Prize (2009). He was the President of Network of Academies of Sciences of Islamic Countries (NASIC), Vice President TWAS (Italy), Foreign Fellow Korean Academy of Science & Technology, President Pakistan Academy of Sciences (2003-2006) and (2011 – 2014). He was the Federal Minister for Science and Technology of Pakistan (2000 – 2002), Federal Minister of Education (2002) and Chairman Higher Education Commission/Federal Minister (2002-2008), Coordinator General of COMSTECH (OIC Ministerial Committee) (1996-2012), and the Editor-in-Chief of Current Medicinal Chemistry.